Shares of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) ended Friday session in green amid volatile trading. The shares closed up +0.20 points or 0.59% at $34.22 with 1,132,983 shares getting traded. Post opening the session at $34.02, the shares hit an intraday low of $32.72 and an intraday high of $34.58 and the price vacillated in this range throughout the day. The company has a market cap of $1.28 billion and the numbers of outstanding shares have been calculated to be 37.28 million shares.
Pacira Pharmaceuticals Inc (PCRX) on Sept. 21, 2016 announced new data regarding the benefit of EXPAREL® (bupivacaine liposome injectable suspension) for patients undergoing third molar (wisdom teeth) extraction, marking the official launch of the product to the oral surgeon community. EXPAREL is a local analgesic that provides prolonged non-opioid postsurgical pain control.
As the nation battles the opioid addiction crisis, there is a particular opportunity to offer opioid alternatives to treat postsurgical pain in oral surgery patients. A recent study published in the Journal of the American Medical Association (JAMA) found an exceedingly high percentage of patients between 14 and 24 years of age are prescribed opioids for surgical tooth extractions; for many patients, this may be their first exposure to opioids. According to a government report, the highest rates of opioid abuse are seen among 18 to 25 year olds.
“We are pleased to work with the oral surgery community to help make EXPAREL available to patients undergoing third molar extraction and other relevant oral and maxillofacial procedures where long-lasting pain control is required to help patients get through the immediate postsurgical period,” said Dave Stack, Chief Executive Officer and Chairman of Pacira. “We believe the ability to offer patients and their caregivers—often their parents, in the case of third molar extraction patients—a safe and effective non-opioid option will not only help reduce overreliance on opioids, but also mitigate exposure to their unwanted side effects and the potential for long-term safety risks like opioid misuse, abuse, or addiction.”
Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) ended Friday session in green amid volatile trading. The shares closed up +0.43 points or 0.71% at $61.41 with 2,507,794 shares getting traded. Post opening the session at $61.17, the shares hit an intraday low of $59.60 and an intraday high of $62.23 and the price vacillated in this range throughout the day. The company has a market cap of $3.27 billion and the numbers of outstanding shares have been calculated to be 52.89 million shares.
On September 29, 2016 Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company (“Catabasis”), and Sarepta Therapeutics, Inc. (SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics (“Sarepta”), announced a joint research collaboration to explore a combination drug treatment approach for Duchenne muscular dystrophy (DMD). The two companies will contribute their respective expertise to study an exon skipping treatment developed by Sarepta, together with an oral NF-kB inhibition treatment developed by Catabasis in a mouse model of DMD.
“We are excited to work with Sarepta on this joint research collaboration, which to our knowledge is the first time two companies are testing a combination of investigational therapies to treat Duchenne. Although we believe edasalonexent (CAT-1004) has the potential to be a disease-modifying monotherapy, we think there is benefit to exploring innovative ways to make the most meaningful difference in this devastating disease”, said Jill C. Milne, Ph.D., chief executive officer of Catabasis. “In addition to our continued development of edasalonexent, we are pleased to take the first step via this collaboration to determine if edasalonexent may be complementary to an exon-skipping treatment strategy in the treatment of DMD using a preclinical model.”
“We recognize the extreme unmet medical need in DMD and are committed to determining the best treatment strategies for patients affected by Duchenne,” said Edward Kaye, M.D., Sarepta’s chief executive officer. “We believe exon skipping has the potential to target the underlying genetic cause of the disease by restoring the mRNA reading frame to produce dystrophin in skeletal muscle. We are pleased to initiate activities with Catabasis to evaluate a potential combination treatment approach of exon-skipping and NF-kB inhibition in DMD.”